We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
Gene-therapy companies got a boost during Monday trading after Novartis AG's (NVS) $8.7 billion deal to buy AveXis Inc. (AVXS), making good on CEO Vasant Narasimhan's promise to strike deals to refocus the company. Analysts at Chardan said Regenxbio Inc. (RGNX), Spark Therapeutics Inc. (ONCE) and Nightstar Therapeutics PLC (NITE) could be among the company's next targets. Regenxbio shares jumped 22% to $33.05 during Monday trading, while Spark shares rose 14% to $70.75 and rand Nightstar rose 8.1% to $12.65. (imani.moise@wsj.com; @moisenoise)
(END) Dow Jones Newswires
April 09, 2018 12:44 ET (16:44 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
